There may be an effective new treatment for people with bladder cancer that doesn't respond to a frontline therapy.

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients ...

BofA analyst Allen Lutz notes Ro Health, a direct competitor to Hims & Hers (HIMS), announced that the company is working with Eli Lilly ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) declared that its Board of Directors has approved a stock buyback program on Monday, December 9th, RTT News reports. The company plans to repurchase ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...